Antibodies Targeting the ErbB2/ErbB3/IGF-1R Complex as Therapeutics for ErbB2 Positive Breast Cancer
Antibodies Targeting the ErbB2/ErbB3/IGF-1R Complex as Therapeutics for ErbB2 Positive Breast Cancer
靶向 ErbB2/ErbB3/IGF-1R 复合物的抗体作为 ErbB2 阳性乳腺癌的治疗药物
批准号：
270041
负责人：
Liu Jianghai
金额：
$9.83万
依托单位国家：
加拿大
项目类别：
Fellowship Programs
财政年份：
2012
资助国家：
加拿大
项目状态：
已结题
起止时间：
2012-10-01 至 2015-10-01
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The use of the antibody trastuzumab to inhibit human epidermal growth factor receptor 2 (erbB2), which is present on specific types of breast cancer, is a paradigm shift in cancer therapy, as it provides a more specific and less toxic approach to treat br
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
